Comanche Biopharma
Design & Creative · Biotechnology
$148.6Mtotal raised · 3 rounds on record
$75Mlatest round · Series B · Jan 2024 · 2 yr ago
4backers · Atlas Venture, Broadview Ventures
50+team · employees, estimated range
Overview
Our purpose is. Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia.
Key facts
These are the key facts about Comanche Biopharma on Alion as of Nov 13, 2026. Comanche Biopharma is headquartered in Concord, United States. It was founded in 2020. It has raised $148.6M in 3 funding rounds. The latest round is Series B of $75M, announced in 2024.
- Headquarters
- Concord, United StatesAlion company profile, updated Nov 4, 2026
- Founded
- 2020Alion company profile, updated Nov 4, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $148.6MSum of 3 equity rounds Alion knows
- Latest round
- Series B · $75M · Jan 16, 2024Press report · krqe.com
Official records
Funding and backers
Total raised
$148.6M
3 rounds on record
Latest round
$75M
Series B · Jan 2024 · 2 yr ago
Team
51-200
employees, estimated range
Backers
4
Atlas Venture, Broadview Ventures
The money's age
Long since its last round
33 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 16, 2024
Raised a round Series B $75M
Jun 28, 2021
Raised a round Venture round $36.1M · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jan 2024 | $75M | — | krqe.com |
| Venture round | Dec 2023 | $37.5M | — | SEC Form D |
| Venture round | Jun 2021 | $36.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Comanche Biopharma Corp. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Paul AntinoriExecutive OfficerSEC Form D
Allison AugustExecutive OfficerSEC Form D
Michael YoungExecutive OfficerSEC Form D
Thomas JohnsonExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Menu principal. Caution: Novostia technology is an investigational device not yet approved for sale.
THE COMPANY - MALARVX MalarVx Inc. is a biopharmaceutical company focused on developing an effective malaria vaccine.
Alveron Pharma is developing a unique coagulationplatform technology with the world.
Rethinking treatment of obstructive sleep apnea. Mosanna is developing an easy-to-use nighttime nasal spray to help restore the body's…
Restoring what's lost. Arnatar is reimagining RNA medicines to precisely silence disease drivers or restore what's missing. Through our…
Discover our mission and how the BUSUP project was born. Our purpose is to link employees, companies and bus operators.
People
Paul Antinori
Executive Officer
Allison August
Executive Officer
Michael Young
Executive Officer
Thomas Johnson
Executive Officer, Director
Arthur Levin
Director
Brendan Bulik-Sullivan
Director
Muzammil Mansuri
Director
Ann Taylor
Director
Clive Meanwell
Director
Allyson Felix
Director
Ketan Patel
Director
David Grayzel
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Broadview VenturesVia a fund
Atlas VentureVia a fund
F-Prime CapitalVia a fund
194 portfolio companies: AblePay Health, Arboretum LifeSciences, Inc., Arexera Therapeutics and 191 more
GVVia a fund
569 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically debilitatingPreeclampsia, a serious obstetric complication, is a leading cause of near-term morbidity and mortality for mothers and th
Read more
Report
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
ILAP aims to accelerate time to market, facilitating faster patient access to clinically important and promising medicines being developed to address significant health needsPreeclampsia is a serious obstetric complication that threatens the life of both
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Concord
United States
HQ
Contact Us
50-200 est. staff
Concord, MA 01742
How to cite this page
Alion, "Comanche Biopharma: key facts", as of Nov 13, 2026. https://alion.io/company/comanchebiopharma
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0